Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures

James M. Smith, Priya Srinivasan, Ryan S. Teller, Yungtai Lo, Chuong T. Dinh, Patrick F. Kiser, Betsy C. Herold

Research output: Contribution to journalArticle

21 Scopus citations


Preclinical HIV prevention models use either a single high-dose viral challenge in depot medroxyprogesterone acetate- treated macaques or repeated viral challenges in cycling macaques. We tested the efficacy of an intravaginal tenofovir disoproxil fumarate (TDF) ring in a model combining repeated 30-mg injections of depot medroxyprogesterone acetate every 6 weeks with vaginal viral challenges weekly for 12 weeks. Twelve macaques were randomized to TDF or placebo rings. All placebo macaques became infected after a median of 2 exposures, whereas only 1 TDF macaque became infected at the eighth exposure (P = 0.0012). The TDF ring provides durable protection in a stringent challenge model.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Issue number1
Publication statusPublished - Jan 1 2015



  • Depo-Provera
  • Intravaginal ring
  • PrEP
  • TDF
  • macaque

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this